NCT06690034

Brief Summary

Zinc influences the production and action of erythropoietin (EPO), a hormone produced by the kidneys that stimulates red blood cell production. However, further research is needed to fully understand the mechanisms and to develop evidence-based guidelines for zinc supplementation in patient with Diabetic kidney disease. this study aim to detect serum zinc level in patient with Diabetic kidney disease "CKD" and Study of association between serum zinc and serum urea, creatinine, GFR, hemoglobin ,HbA1c in DKD

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Dec 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Dec 2025Jan 2027

First Submitted

Initial submission to the registry

November 13, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 15, 2024

Completed
1 year until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

November 15, 2024

Status Verified

November 1, 2024

Enrollment Period

1 year

First QC Date

November 13, 2024

Last Update Submit

November 13, 2024

Conditions

Diabetic Nephropathy Type 2

Keywords

serum zinc level

Outcome Measures

Primary Outcomes (1)

  • zinc level

    prevalence of hypozincemia in Diabetic kidney disease

    baseline

Study Arms (2)

group 1

Patient with Diabetic kidney disease according to KDIG

group 2

patients with diabetes without chronic kidney disease

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with diabetic kidney disease and Diabetic patient without kidney disease as a control

You may qualify if:

  • Patients with diabetic kidney disease

You may not qualify if:

  • patients on dialysis. Patient refuse to participate
  • Other renal disease "lupus nephritis,GlomeruloNephritis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Takao T, Yanagisawa H, Suka M, Yoshida Y, Onishi Y, Tahara T, Kikuchi T, Kushiyama A, Anai M, Takahashi K, Wakabayashi Sugawa S, Yamazaki H, Kawazu S, Iwamoto Y, Noda M, Kasuga M. Synergistic association of the copper/zinc ratio under inflammatory conditions with diabetic kidney disease in patients with type 2 diabetes: The Asahi Diabetes Complications Study. J Diabetes Investig. 2022 Feb;13(2):299-307. doi: 10.1111/jdi.13659. Epub 2021 Oct 7.

    PMID: 34533892BACKGROUND

Central Study Contacts

Salma Mohamed Sayed, resident doctors

CONTACT

+2 01060342916salma.16266351@med.aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor at nephrology unit ,internal medicine department

Study Record Dates

First Submitted

November 13, 2024

First Posted

November 15, 2024

Study Start

December 1, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

January 1, 2027

Last Updated

November 15, 2024

Record last verified: 2024-11